In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D ...

That Ozempic (or Wegovy, the name by which the weight-loss version of the drug semaglutide is marketed) should have proliferated in an industry that has always venerated thinness will hardly come as a ...

People are seeking out 'microdoses' of Ozempic and other weight-loss drugs. Medical professionals say there's pros and cons.

The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam.Most Read from ...

Semaglutide belongs to a class of prescription medications that mimic a hormone your body naturally produces after you eat. This hormone helps your pancreas make insulin, which lowers your blood sugar ...

The term "Ozempic face" is not a medical term, but some use it to describe this type of appearance after weight loss. Here what's fact and fiction.

Safety processes and regulations apply to custom-made medicines, which differ from traditional pharmacies. Now, however, ...

A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...

Novo Nordisk, the maker of the semaglutide products Ozempic and Wegovy, has filed lawsuits against 40 pharmacies, spas and ...

By Arasu Kannagi Basil and Prakhar Srivastava (Reuters) -Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer ...

Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...